The Funding-First Filter
MethodologyComments
ghostwriting is standard in industry sponsored trials.
I disagree that it is the standard across the board. Many industry partnerships now require strict transparency agreements to prevent that exact issue.
Does the results section really come before the abstract... or should the methodology be the absolute priority since that defines if the results even matter? I wonder if some fields have different standards for what counts as a 'stretch' in the conclusion...
I recall a similar debate during the early days of the pharmaceutical transparency movement. Do you think this workflow handles 'ghostwriting' where the funders aren't the listed authors?
Open data mandates in some disciplines make this filter less critical. If the raw dataset is linked, the incentive structure is secondary to the reproducible code.
Hypothetically, could the funding source still influence which datasets are actually released to the public? Even with open data, the selection of what is reported might still follow the incentive structure.
This is how it works in public health planning. We've seen too many 'breakthrough' soil studies funded by fertilizer giants that look great in the abstract but fail in actual field trials.